{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:26:20Z","timestamp":1787023580263,"version":"build-2736575974"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Kentucky Nephrology Research Trust"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), also known as autoimmune polyglandular syndrome type 1, is an autosomal recessive disorder of thymic T cell negative selection that results in autoimmune destruction of various endocrine and extra-endocrine tissues. The classic clinical triad of the syndrome includes hypoparathyroidism (hypoPT), chronic mucocutaneous candidiasis (CMC), and adrenal insufficiency, while involvement of thyroid, pancreas, gonads, and ectodermal tissues are also frequently observed. Historically, treatment for hypoPT, the most common endocrine manifestation of APECED, has posed a unique challenge. Conventional therapy with oral calcium and active vitamin D analogs is often complicated by the presence of malabsorption and esophageal disorders, which are prevalent in APECED patients. Moreover, supplementation with oral calcium and active vitamin D analogs without correction of the underlying PTH insufficiency can result in renal and other soft-tissue calcifications. Short-acting PTH therapies, which have been used off-label in the treatment of hypoPT, fail to mimic normal parathyroid physiology due to their brief half-lives and can result in fluctuations of serum calcium levels between hypocalcemia and hypercalcemia. Long-acting PTH analogs have recently been developed to more closely mimic physiologic PTH activity. One such agent, palopegteriparatide, a prodrug of PTH (1,34), has shown promise to be the first hormone replacement therapy for hypoPT. We report our experience in 4 patients with APECED-associated hypoPT who initiated treatment with palopegteriparatide and were followed over the subsequent 4-15\u00a0mo period. We observed a robust calcemic response to treatment during this follow-up window with wide fluctuations in serum calcium during this period of dose titration. These early observations highlight the effectiveness of palopegteriparatide in patients with APECED, enabling the discontinuation of oral calcium and active vitamin D supplements. They also highlight the question of whether etiology-specific differences in responsiveness may influence dose requirements and calcemic stability.<\/jats:p>","DOI":"10.1093\/jbmrpl\/ziag114","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T11:45:52Z","timestamp":1784288752000},"source":"Crossref","is-referenced-by-count":0,"title":["Palopegteriparatide treatment for hypoparathyroidism in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy: a case series and literature update"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-2369-4906","authenticated-orcid":false,"given":"Haley","family":"Akers","sequence":"first","affiliation":[{"name":"University of Kentucky College of Medicine , Lexington, KY 40536 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0375-7223","authenticated-orcid":false,"given":"Lucas","family":"Maxey","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Kentucky College of Medicine , Lexington, KY 40536 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0641-2156","authenticated-orcid":false,"given":"Kadin","family":"Ashley","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Bone and Mineral Metabolism, University of Kentucky Healthcare , Lexington, KY 40536 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3894-5224","authenticated-orcid":false,"given":"Florence","family":"Lima","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Bone and Mineral Metabolism, Hartmut H. Malluche MD Bone Research Laboratory, University of Kentucky College of Medicine , Lexington, KY 40536 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7489-521X","authenticated-orcid":false,"given":"Madhumathi","family":"Rao","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Bone and Mineral Metabolism, University of Kentucky College of Medicine , Lexington, KY 40536 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"issue":"11","key":"2026081723021367800_ref1","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1007\/s40618-021-01585-6","article-title":"Autoimmune polyendocrine syndrome type 1: an Italian survey on 158 patients","volume":"44","author":"Garelli","year":"2021","journal-title":"J Endocrinol Investig"},{"issue":"4","key":"2026081723021367800_ref2","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/ng1297-393","article-title":"Positional cloning of the APECED gene","volume":"17","author":"Nagamine","year":"1997","journal-title":"Nat Genet"},{"issue":"19","key":"2026081723021367800_ref3","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.3389\/fimmu.2018.02570","article-title":"Chronic mucocutaneous candidiasis in autoimmune polyendocrine syndrome type 1","volume":"9","author":"Humbert","year":"2018","journal-title":"Front Immunol"},{"issue":"2","key":"2026081723021367800_ref4","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1084\/jem.20091669","article-title":"Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines","volume":"207","author":"Kisand","year":"2010","journal-title":"J Exp Med"},{"issue":"8","key":"2026081723021367800_ref5","doi-asserted-by":"publisher","first-page":"103135","DOI":"10.1016\/j.autrev.2022.103135","article-title":"Autoimmune polyendocrine syndrome type 1: clinical manifestations, pathogenetic features, and management approach","volume":"21","author":"Bjorklund","year":"2022","journal-title":"Autoimmun Rev"},{"issue":"8","key":"2026081723021367800_ref6","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1080\/1744666X.2021.1925543","article-title":"Clinical, immunological, and genetic features in 938 patients with autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED): a systematic review","volume":"17","author":"Sharifinejad","year":"2021","journal-title":"Expert Rev Clin Immunol"},{"issue":"2","key":"2026081723021367800_ref7","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1097\/MCG.0b013e31827356e1","article-title":"Gastrointestinal manifestations in APECED syndrome","volume":"47","author":"Kluger","year":"2013","journal-title":"J Clin Gastroenterol"},{"issue":"1","key":"2026081723021367800_ref8","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12887-025-05458-2","article-title":"Renal disorders in autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED): a systematic review","volume":"25","author":"Shafiei","year":"2025","journal-title":"BMC Pediatr"},{"issue":"6","key":"2026081723021367800_ref9","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3389\/fendo.2020.00109","article-title":"Severe phenotype of APECED (APS1) increases risk for structural bone alterations","volume":"11","author":"Laakso","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"20","key":"2026081723021367800_ref10","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1056\/NEJMe2403419","article-title":"JAK inhibition immunotherapy for APS-1","volume":"390","author":"Su","year":"2024","journal-title":"N Engl J Med"},{"issue":"7","key":"2026081723021367800_ref11","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1002\/jbmr.2811","article-title":"Pharmacodynamic actions of a long-acting PTH analog (LA-PTH) in thyroparathyroidectomized (TPTX) rats and normal monkeys","volume":"31","author":"Shimizu","year":"2016","journal-title":"J Bone Miner Res"},{"key":"2026081723021367800_ref12","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.jpeds.2018.08.010","article-title":"Long-term parathyroid hormone 1-34 replacement therapy in children with hypoparathyroidism","volume":"203","author":"Winer","year":"2018","journal-title":"J Pediatr"},{"issue":"12","key":"2026081723021367800_ref13","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1002\/jbmr.4673","article-title":"Complications, symptoms, presurgical predictors in patients with chronic hypoparathyroidism: a systematic review","volume":"37","author":"Yao","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"8","key":"2026081723021367800_ref14","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13082368","article-title":"Exploring chronic hypocalcemia: insights into autoimmune polyglandular syndrome type 1-a case study and literature review","volume":"13","author":"Brad","year":"2024","journal-title":"J Clin Med"},{"issue":"6","key":"2026081723021367800_ref15","doi-asserted-by":"publisher","first-page":"2680","DOI":"10.1210\/jc.2009-2464","article-title":"Long-term treatment of 12 children with chronic hypoparathyroidism: a randomized trial comparing synthetic human parathyroid hormone 1-34 versus calcitriol and calcium","volume":"95","author":"Winer","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"2026081723021367800_ref16","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.bone.2018.09.018","article-title":"Advances in the treatment of hypoparathyroidism with PTH 1-34","volume":"120","author":"Winer","year":"2019","journal-title":"Bone"},{"issue":"1","key":"2026081723021367800_ref17","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s11914-025-00905-6","article-title":"PTH substitution therapy for chronic hypoparathyroidism: PTH 1-84 and palopegteriparatide","volume":"23","author":"Palermo","year":"2025","journal-title":"Curr Osteoporos Rep"},{"issue":"4","key":"2026081723021367800_ref18","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1210\/clinem\/dgae693","article-title":"Efficacy and safety of TransCon PTH in adults with hypoparathyroidism: 52-week results from the phase 3 PaTHway trial","volume":"110","author":"Clarke","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026081723021367800_ref19","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/jbmr.4726","article-title":"Efficacy and safety of parathyroid hormone replacement with TransCon PTH in hypoparathyroidism: 26-week results from the phase 3 PaTHway trial","volume":"38","author":"Khan","year":"2023","journal-title":"J Bone Miner Res"},{"key":"2026081723021367800_ref20","doi-asserted-by":"publisher","first-page":"115977","DOI":"10.1016\/j.bone.2021.115977","article-title":"Therapy with PTH 1-34 or calcitriol and calcium in diverse etiologies of hypoparathyroidism over 27 years at a single tertiary care center","volume":"149","author":"Winer","year":"2021","journal-title":"Bone"}],"container-title":["JBMR Plus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmrplus\/advance-article-pdf\/doi\/10.1093\/jbmrpl\/ziag114\/69636794\/ziag114.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/10\/9\/ziag114\/69636794\/ziag114.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/10\/9\/ziag114\/69636794\/ziag114.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:02:20Z","timestamp":1787022140000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article\/doi\/10.1093\/jbmrpl\/ziag114\/8738603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,8,10]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmrpl\/ziag114","relation":{},"ISSN":["2473-4039"],"issn-type":[{"value":"2473-4039","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,7,21]]},"article-number":"ziag114"}}